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Abstract
Background
Targeted testing and treatment of TB infection to prevent disease is a pillar of TB elimination. Despite recent global commitments to greatly expand access to preventive treatment
for TB infection, there remains a lack of research on how best to expand preventive treatment programs in settings with high TB burdens.
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We conducted implementation research in Lima, Peru, around a multifaceted intervention to
deliver TB preventive treatment to close contacts of all ages, health care workers, and people in congregate settings. Key interventions included use of the interferon gamma release
assay (IGRA), specialist support for generalist physicians at primary-level health facilities,
and treatment support by community health workers. We applied a convergent mixed methods approach to evaluate feasibility and acceptability based on a care cascade framework.
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Findings
During April 2019-January 2020, we enrolled 1,002 household contacts, 148 non-household
contacts, 107 residents and staff of congregate settings, and 357 health care workers.
Cumulative completion of the TB preventive care cascade was 34% for contacts <5 years
old, 28% for contacts 5–19 years old, 18% for contacts �20 years old, 0% for people in congregate settings, and 4% of health care workers. IGRA testing was acceptable to adults
exposed to TB. Preventive treatment was acceptable to contacts, but less acceptable to
physicians, who frequently had doubts about prescribing preventive treatment for adults.
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Implementation research on TB infection treatment in Peru

Community-based treatment support was both acceptable and feasible, and periodic homevisits or calls were identified as facilitators of adherence.

Conclusions
We attempted to close the gap in TB preventive treatment in Peru by expanding preventive
services to adult contacts and other risk groups. While suboptimal, care cascade completion
for adult contacts was consistent with what has been observed in high-income settings. The
major losses in the care cascade occurred in completing evaluations and having doctors
prescribe preventive treatment.

Introduction
Globally, more than 10 million people develop tuberculosis (TB) each year and 1.5 million die
—more than 4,000 people each day. Despite the availability of curative treatment for TB disease since the late 1940s, and preventive treatment for TB infection since the late 1950s, rates
of TB have dropped at an extremely slow 1.5 to 1.8 percent per annum over the last 20 years
[1]. The Zero TB Initiative is an emerging network of coalitions seeking to rapidly drive down
TB case rates in geographically defined zones by deploying the evidence-based strategy of
simultaneously increasing case-finding, access to treatment for all forms of TB disease, and
access to TB preventive treatment to prevent development of TB disease [1]. Widespread
access to TB preventive treatment until recently has not been the norm outside of high-income
countries, but it is necessary to achieve significant reductions in the global TB burden [2,3].
Preventive treatment of TB infection in close contacts and high-risk communities is a pillar
of TB elimination [4]. In high-income countries, TB preventive treatment has been targeted to
multiple groups at risk, including people who have been in close contact with someone with
TB, people living with HIV, health care workers, and people in prisons, among others [5]. In
contrast, following decades of “minimalist” guidance from international health agencies to
low- and middle-income countries [6], TB programs in countries with high TB burdens have
focused TB preventive treatment only on child contacts <5 years old [7] and people living
with HIV [8], the groups with perceived highest risk. However, these two groups contribute
relatively little to the global TB burden, accounting for around 10% of notified cases in 2019
[9].
In 2018, World Health Organization guidance for all countries, regardless of TB burden or
economic status, came into line with best practices that call for all locally relevant populations
with elevated risk of TB to be screened and treated for TB infection [10,11]. At the United
Nations High Level Meeting on tuberculosis, countries of the world committed to ensure that
30 million people would receive preventive treatment by 2022 [12]. However, only a fraction
of that goal had been achieved by 2020 [9]. Implementation research is lacking on effective
strategies to achieve changes in local programs to close this TB preventive treatment gap in
low- and middle-income settings [13,14].
A coalition of local, national, and international partners launched a TB elimination initiative in Lima, Peru, a middle-income setting with moderate incidence and low HIV prevalence.
Key components of the initiative included community-based active case-finding with x-ray
vans [15] and reaching known high-risk populations with TB infection testing and preventive
treatment. As part of the latter component, we sought to explore strategies for changing practices around testing and treatment for TB infection, attempting to close the preventive
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treatment gap by expanding its use beyond only young child contacts and people living with
HIV. We conducted implementation research around a multifaceted intervention to provide
preventive treatment to older contacts, health care workers, and people living in congregate
settings.

Materials and methods
Study population and setting
We evaluated a multifaceted intervention designed to change practices around the use of TB
preventive treatment, which was implemented in the eastern region of Carabayllo District
(population 261,000) of Lima, Peru. The evaluation included participants enrolled during
April 2019-January 2020.
Peru is a middle-income country with an estimated TB incidence of 119 per 100,000 and
low HIV prevalence in the general population [9]. In the 2015 national drug resistance survey,
7.3% of patients with TB and no prior treatment history had multidrug-resistant TB [16]. TB
treatment and contact management takes place in primary-level health facilities staffed by generalist doctors. The tuberculin skin test (TST) rather than the blood-based interferon gamma
release assay (IGRA) is used to test for TB infection.
National TB guidelines [17] mandate preventive treatment with 6 months of isoniazid following rule-out of active TB disease for five groups: (a) children <5 years old who are contacts
of patients with pulmonary TB, regardless of TST result; (b) people 5–19 years who are contacts of pulmonary patients with pulmonary TB and who have TST results of �10 mm induration; (c) people living with HIV, regardless of TST result; (d) health care workers with TST
conversion; and (e) people with certain medical comorbidities, based on clinician judgement.
The guidelines neither mandate nor prohibit preventive treatment for adult close contacts, but
few are typically treated [18]. As isoniazid is the only preventive treatment medication used in
this setting, the guidelines recommend that preventive treatment not be given to contacts of
patients with drug-resistant TB because of presumed resistant infection, although new guidance to use levofloxacin is currently under consideration.

Intervention approach
In 2019, the non-governmental organization Socios En Salud in collaboration with the North
Lima health authority (DIRIS Lima Norte) developed an intervention aimed to promote TB
preventive treatment for close contacts of all ages, as well as for health care workers and people
in congregate settings that had recently had TB cases. The intervention approach was designed
to address barriers encountered in 2015–2016 during a previous effort to improve preventive
treatment practices among child contacts in the same population [19] and informed by local
qualitative observations [20,21] (S1 Table). The approach was developed with Socios En Salud
staff who participated in the 2015–2016 intervention, doctors and administrators at the public
health facilities, the investigators, and local residents.
A Socios En Salud field team worked with participants in their communities, while health
facility clinicians were responsible for all clinical management (Fig 1). Key elements of the
intervention included offering testing to all persons in key populations, using IGRA testing
(QuantiFERON TB Gold Plus, Qiagen, Germantown, MD), performing tests at locations convenient to participants, contracting specialists (pulmonologist and pediatrician) to visit primary-level health facilities to support generalist doctors in clinical evaluations and
management of preventive treatment, and community-based treatment support tailored to
participant preferences.
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Fig 1. Key procedures for intervention participants. Abbreviations: TB = tuberculosis, IGRA = interferon gamma
release assay, TST = tuberculin skin test.
https://doi.org/10.1371/journal.pone.0247411.g001

Intervention participants
A Socios En Salud field team comprising nurses, nurse technicians, and community health
workers (community members with basic training on health issues) recruited three target
groups of participants: close contacts of TB patients, residents and staff of congregate settings,
and health care workers. To identify close contacts, the field team worked with the TB programs at the nine public health facilities in the eastern region of Carabayllo to conduct contact
investigations for all patients newly diagnosed with TB; all contacts in this region were thus
recruited for the intervention. The congregate setting participants represented a convenience
sample, as health facility staff identified for intervention congregate settings that had recently
had TB cases, including a drug rehabilitation center, a residential center for the elderly, and a
government child-care center. Finally, the staff of the nine health facilities were invited to
participate.

Intervention implementation
The field team counseled potential participants about TB infection and preventive treatment,
informing them that if they enrolled, they could access free testing for TB infection and followup during treatment, if indicated. People who were currently being treated for TB disease were
ineligible for enrollment. Participants <10 years old were recommended to receive a TST due
to the difficulty of phlebotomy, while participants 10 years and older were first offered an
IGRA. However, participants or their guardians were free to choose either test. The field team
performed TST and IGRA phlebotomy in locations convenient to participants (e.g., at home
or at a local health facility). TSTs were read 48–72 hours after placement, with an induration of
10 mm or greater considered positive. IGRAs were processed at the Socios En Salud
laboratory.
Physicians at the primary-level health facilities were responsible for the diagnosis of TB disease, the decision to prescribe preventive treatment, and the management of treatment. The
intervention contracted two specialists (an adult pulmonologist and a pediatric pulmonologist)
from hospitals in Lima to periodically visit the health facilities to provide consultations and
mentorship to these physicians; a Socios En Salud pediatrician also assisted with consultations.
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The field team helped participants make appointments for evaluation procedures, which
included chest radiography and clinical evaluation, and could include sputum testing.
If TB preventive treatment was prescribed, the field team offered participants follow-up
support. Participants were asked whether they would like to receive weekly, biweekly, or
monthly phone calls or visits from community health workers, and they were offered free automated daily SMS reminders to take medications (Memora Health, San Francisco, CA). Participants were counseled about potential adverse events and given the phone number of a field
team member to call in the event of concerning symptoms. Field team members provided the
type of support requested by participants and contacted participants monthly to administer an
adverse event questionnaire (S1 Appendix). The questionnaire asked whether participants had
experienced specific symptoms consistent with reaction to isoniazid treatment in the past
month, and the field team referred participants for evaluation as necessary.

Mixed-methods evaluation
We conducted a convergent mixed methods approach to evaluate key implementation outcomes of feasibility and acceptability [22], structuring the evaluation around a care cascade
framework [23,24] (Fig 2). The quantitative evaluation focused on determining the percentage
of participants completing each step of the care cascade among those eligible to complete it.
The cumulative percentage completing the entire cascade was calculated by multiplying the
percentages completing the individual steps [23]. To explain high or low completion of specific
steps, we analyzed qualitative data from focus group discussions. We integrated quantitative
and qualitative findings to draw conclusions about the acceptability of TB infection testing and
preventive treatment, as well as the feasibility of IGRA testing and community-based treatment support.
Quantitative analysis. Study staff prospectively collected quantitative data on TB infection testing, which was managed by Socios En Salud, as well as participants’ preferences for
treatment support (S2 Appendix) and self-reported adverse events (S1 Appendix). Quantitative data on other TB evaluation procedures, prescription, treatment initiation, and treatment
completion were collected retrospectively from medical records.
To quantitatively evaluate the care cascade, we assessed completion of TB infection testing
among enrolled participants; completion of TB evaluation (defined as a minimum of clinical
examination and chest radiography) among those with a positive test for infection; prescription of preventive treatment among those potentially eligible for treatment; initiation of preventive treatment among those for whom treatment was prescribed; and completion of
preventive treatment among those who initiated treatment. For the purposes of this evaluation,

Fig 2. TB infection care cascade framework and key acceptability and feasibility outcomes of study. Abbreviations:
TB = tuberculosis, IGRA = interferon gamma release assay, TST = tuberculin skin test.
https://doi.org/10.1371/journal.pone.0247411.g002
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we used the following criteria to define potential eligibility for preventive treatment: (1) participants had a positive test for TB infection or were child contacts <5 years old, (2) participants
underwent a clinical evaluation and had a chest radiograph, and were not diagnosed with
active TB, and (3) for participants who were contacts, the patient to whom they had been
exposed had not been diagnosed with drug-resistant TB.
Characteristics associated with completion of care cascade steps were evaluated statistically
using a modified Poisson regression with robust error variances to estimate risk ratios adjusted
for risk group, age group, and sex. We used age groups with policy or clinical relevance (e.g.,
children <5 have different eligibility criteria for treatment, age 35 is frequently used as a
benchmark for increased risk of isoniazid hepatotoxicity [25]). The outcome of completing an
infection test was assessed among all enrolled participants. The outcome of a positive TB infection test was assessed among all people with a test result. The outcome of completing evaluation was assessed among people <5 years old and those with a positive infection test. The
outcome of initiating preventive treatment was evaluated among participants eligible for preventive treatment after evaluation, combining the cascade steps of prescription and initiation.
The outcome of preventive treatment completion was evaluated among participants who initiated treatment. Statistical analyses were performed in SAS v9.4 (SAS Institute, Cary, NC).
Qualitative analysis. Qualitative data were collected through focus group discussions
held as part of the planning process and during implementation to solicit feedback for intervention improvement (Table 1). These focus group discussions were meant to inform implementation and to provide preliminary insight into implementation barriers, which could later
be explored through more rigorous methods. Overall, eight focus group discussions included
34 community participants and 5 health care worker participants; 30 (88%) participants were
female. Focus group discussions were audio recorded and transcribed, and transcripts were
uploaded into the qualitative analysis software Dedoose [26]. Coding followed a framework
analysis approach [27] guided by the results of the quantitative analysis, and focused on identifying barriers and facilitators to completion of each cascade step. Qualitative methods adhered
to the Consolidated Criteria for Reporting Qualitative Research (COREQ) [28]; details can be
found in S3 Appendix.

Ethical considerations
This study was approved by the Ethics Committee of the Universidad Peruana Cayetano Heredia and the Institutional Review Board of Harvard Medical School. Verbal informed consent
Table 1. Description of focus group discussions.
Group Project
phase

Participant description

Number of
participants

Topics discussed (duration)

1

Planning

Adults 18–45 years old from families affected by TB

5

2

Planning

Adults 46–70 years old from families affected by TB

6

What preventive treatment support strategies would be acceptable and
effective in participants’ communities (30 minutes)

3

Planning

Caregivers from families affected by TB

6

4

Feedback

Adult contacts who completed treatment

5

5

Feedback

Adult contacts who did not complete treatment

2

6

Feedback

Caregivers of child contacts who completed
treatment

5

7

Feedback

Caregivers of child contacts who did not complete
treatment

5

8

Feedback

Doctors (2 general, 1 pulmonologist) and nurses (2)
who managed TB preventive treatment in public
health facilities

5

Experiences during preventive treatment, factors that supported
uptake and adherence, challenges faced, and ways in which future
interventions could address these challenges (60 minutes)

Barriers and facilitators to TB infection management (90 minutes)

https://doi.org/10.1371/journal.pone.0247411.t001
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was obtained from all intervention participants, with parental consent for children <18 years
old and assent from children 8–17 years old. Consent was obtained separately for the initial TB
infection evaluation and for follow-up during TB infection treatment. Participants were free to
decline evaluation procedures or intervention components without withdrawing from the
study. A waiver of written informed consent was granted on the grounds that study activities
constituted no more than minimal risk and that requiring written informed consent for routine procedures in a programmatic setting would not be feasible.
Verbal informed consent was obtained for all community focus group participants. A
waiver of written informed consent was granted on the grounds that participation constituted
no more than minimal risk and that complete confidentiality could best be assured in this way
since a written consent form would be the only study document recording participants’
names. Written informed consent was obtained for health care worker focus group participants. Participants were provided transport (except for those participating in the videoconference discussion) and a gift card for the equivalent of 10 USD.

Results
TB preventive treatment care cascade completion
We enrolled 1,614 participants for TB infection evaluation: 1,002 household contacts, 148
non-household contacts, 107 residents and staff of congregate settings, and 357 health care
workers. Females comprised 57% of household contacts, 63% of non-household contacts, 36%
of congregate setting participants, and 73% of health care workers (S2 Table). Overall, cumulative completion of the TB preventive care cascade was 34% for contacts under 5 years old, 28%
for contacts 5–19 years old, 18% for contacts at least 20 years old, 0% for people in congregate
settings, and 4% for health care workers (Fig 3). The cascade step with the poorest completion
varied among groups (S3 Table).
Overall, 1534 (95%) of enrolled participants had a TB infection test result, of whom 32% of
household contacts, 18% of non-household contacts, 30% of health care workers, and 22% of
people in congregate settings had a positive test result. The prevalence of infection increased
with age group and was higher among contacts than other risk groups (Table 2). Overall, 59%
of eligible participants completed evaluation, with health care workers significantly less likely
to complete evaluation following a positive infection test than contacts (adjusted risk ratio
[aRR] = 0.25, 95% confidence interval [CI] 0.16–0.38). Among participants eligible for preventive treatment after evaluation, adults were significantly less likely to initiate treatment than

Fig 3. TB preventive treatment care cascade for contacts, people in congregate settings, and health care workers.
Cumulative completion of each cascade step is calculated by calculating the percent who completed each step out of
those eligible to complete it and then multiplying these percentages.
https://doi.org/10.1371/journal.pone.0247411.g003
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Table 2. Predictors of TB infection, evaluation, preventive treatment initiation, and preventive treatment completion.
Participant
characteristics
Risk
group

Age
group

Sex

Contacts

Enrolled

aRR (95% CI) for positive
TB infection test

aRR (95% CI) for
completing evaluation

aRR (95% CI) for initiating
preventive treatment

aRR (95% CI) for completing
preventive treatment

1,150

Reference

Reference

Reference

Not assessed

Congregate
setting

107

0.67 (0.48–0.93)

0.71 (0.46–1.10)

0.62 (0.18–2.17)

Not assessed

Health care
workers

357

0.73 (0.60–0.87)

0.25 (0.16–0.38)

1.37 (0.77–2.45)

Not assessed

0–4 years

115

Reference

Reference

Reference

Reference

5–19 years

445

1.24 (0.74–2.08)

0.89 (0.72–1.10)

0.87 (0.66–1.16)

1.02 (0.79–1.32)

20–35 years

424

2.28 (1.39–3.74)

0.93 (0.75–1.34)

0.56 (0.39–0.82)

1.00 (0.73–1.35)

>35 years

630

3.49 (2.16–5.63)

1.06 (0.91–1.23)

0.39 (0.28–0.55)

1.06 (0.82–1.36)

Female

961

Reference

Reference

Reference

Reference

Male

653

1.21 (1.04–1.41)

0.93 (0.92–1.06)

0.95 (0.75–1.19)

0.89 (0.72–1.09)

For the first three analyses, risk ratios are adjusted for risk group, age, and sex; for the analysis of predictors for completing preventive treatment, risk group is not
assessed because of small numbers of non-contacts initiating treatment. Abbreviations: aRR = adjusted risk ratio, CI = confidence interval, TB = tuberculosis.
https://doi.org/10.1371/journal.pone.0247411.t002

children (aRR for adults 20–35 years old = 0.56, 95% CI 0.39–0.82; aRR for adults >35 years
old = 0.39, 95% CI 0.28–0.55). This gap was mostly attributable to doctors’ not prescribing preventive treatment rather than poor acceptance among participants, as only 49% of eligible participants were prescribed preventive treatment, while 95% of participants who were prescribed
treatment initiated it (S3 Table). Overall, 72% of participants who initiated preventive treatment completed it, with no significant differences by age or sex.

Feasibility and acceptability indicators
TB infection testing. In total, 1,542 (96%) participants agreed to be tested for TB infection, of whom 1,080 (70%) had blood drawn for IGRA testing, and 465 (30%) had a TST
placed; three individuals had both tests performed. In general, the participants followed agebased test type recommendations made by study staff, with 96% of tested children <10 years
old having a TST placed, and 91% of tested adults (�18 years old) having blood drawn for
IGRA. However, among participants 10–17 years old, test choice was variable, with 52%
undergoing IGRA and 48% TST. In total, 462 (99%) of the placed TSTs were read, and 1,075
(>99%) of the blood samples yielded non-indeterminate IGRA results.
Evaluation to diagnose TB infection and rule out TB disease. Clinical evaluation and
chest radiography were completed for 80 (70%) children under 5 years old and for 245 (56%)
older participants with a positive infection test (S3 Table), and 74% of the people who completed the evaluation also had sputum testing performed. Considering chest radiography, sputum testing, and clinical evaluation separately, the evaluation procedure completed by the
fewest participants with TB infection was the clinical evaluation (70% of contacts, 23% of people in congregate settings, 50% of health care workers). In contrast, 90% of contacts, 44% of
people in congregate settings, and 91% of health care workers completed at least one of the
three evaluation procedures. TB disease was diagnosed for 15 individuals (12 household contacts, 2 non-household contacts, and 1 health care worker).
Preventive treatment prescription. Of the 281 participants eligible for preventive treatment after evaluation, only 139 (49%) were prescribed treatment. Prescription did not differ
based on whether or not participants had abnormal chest radiographs (p = 0.744), whether or
not they reported symptoms (p = 0.810). An additional 24 participants were prescribed treatment outside the guideline recommendations. These included participants with a negative
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infection test (n = 11), without an infection test (n = 3), without a chest radiograph (n = 2),
and with exposure to a patient diagnosed with drug-resistant TB (n = 8). For this last group,
we do not know whether the drug-resistant diagnosis was known at the time of prescribing
preventive treatment.
Preventive treatment initiation and completion. Of 163 participants who were prescribed preventive treatment, 155 (95%) initiated treatment, and 112 (72%) of them completed
treatment. Of the forms of treatment support offered to participants at the time of treatment
initiation, 99% of participants accepted automated daily SMS reminders to take medications,
45% requested periodic reminder phone calls, and 60% requested periodic home visits from a
community health worker. In addition, 19% requested another form of support, including visits to a location other than home or help with picking up medications.
Adverse events were reported by 25 (16%) participants during at least one monthly screening (S5 Table). These self-reported adverse events were more common for children <5 years
old (16%) and adults >35 years old (32%) compared to children 5–19 years old (8%) and
adults 20–35 years old (8%) (p = 0.222 for the comparison between the 5–19 and 0–4 age
groups; p = 0.007 for the comparison between the 5–19 and >35 age groups). Two children
and one adult >35 years old had treatment suspended for adverse events. No participants
developed TB disease during treatment.

Facilitators and barriers
Our focus group discussions focused on facilitators and barriers to prescription, initiation, and
completion of treatment. Physicians and nurses identified several factors that prevent physicians from prescribing preventive treatment (Table 3). These included the lack of clear guidance for prescribing treatment for adult contacts in the national guidelines and a perception
that preventive treatment is not for adults. They also mentioned that scientific knowledge
about the efficacy or importance of preventive treatment is not widespread, and that some
physicians believe that preventive treatment can cause drug resistance. A nurse mentioned
that the pulmonologist visits to the health facilities were helpful for convincing doctors at the
health facilities to prescribe treatment.
Regarding treatment initiation, contacts said that the counseling they received about the
purpose of treatment was a motivating factor for accepting preventive treatment. Contacts also
mentioned that they were motivated to accept treatment by the fear of getting sick like their
family members with TB. A nurse mentioned that one barrier to treatment initiation was that
contacts covered by employer-based health insurance could not receive medications from the
public health facilities in their neighborhoods due to the separation of health services by insurance system.
In focus groups, participants described positive support from community health workers,
support from family members, and personal strategies for reminding themselves to take medications as facilitators to adherence. While some participants felt that daily SMS reminders had
been helpful, others did not. For example, one participant said that if a person receives an SMS
reminder while he is out during the day, he might forget it by the time he gets home. The barriers to adherence identified by participants included medication fatigue, adverse events (both
experienced and anticipated), the inconvenience of weekly medication refills, and difficulty
administering pills to children.

Discussion
This study represents an initial attempt to close the gap in TB preventive treatment in a middle-income setting by expanding preventive services to adult contacts and other risk groups.
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Table 3. Representative quotations illustrating facilitators and barriers to TB preventive treatment, by cascade step.
Cascade step

Theme

Participant, focus
group

Example quotation

Prescription
(facilitator)

Specialist consultations help
convince doctors to prescribe

Nurse, group 8

We had the pulmonologist, who knows a lot. And it is good that he was there, because
sometimes when our colleagues had doubts, we as nurses–because there is always more trust
shown toward a doctor than a nurse–we could approach him.

Prescription
(barrier)

Guidelines do not emphasize
treatment

Pulmonologist,
group 8

We are governed by a national guideline, and unfortunately, latent TB infection is given little
importance in the national guideline; there are only a few paragraphs on latent TB infection.

Lack of clear indications in
guidelines

Nurse, group 8

What is not considered in the national guidelines is treatment for adults. . .it is not given, not
considered for all adults. It would be good if they could come out with “positive PPD or IGRA”
or some other indication.

Lack of awareness of scientific
evidence

Doctor, group 8

The doubts about effectiveness are widespread. In my opinion, I consider isoniazid to be a big
help, that it could reduce TB incidence in Peru. But others always ask me about isoniazid or the
evaluation of contacts or preventive treatment for contacts. . .People lack a lot of information,
they may lack technical expertise, they lack awareness.

Perception that treatment is not for
adults

Pulmonologist,
group 8

What happens is that the mentality of the majority of our colleagues is that [preventive]
treatment is for children <5 years old and some people with risk factors.

Concerns about drug resistance

Pulmonologist,
group 8

There are many specialists who will argue that with the large amount of resistance we have,
resistance to isoniazid in our setting, many colleagues argue that [preventive treatment] is not
viable for this reason. But even if they are right, this primary resistance is not more than 10%, so
there will still be benefit to preventive treatment.

Counseling about rationale for
treatment

Female, group 4

I was recently diagnosed with asthma. . .the doctor told me, “You are a person who uses
corticosteroids, which means that you are a patient who is sensitive and at risk. Therefore, you
should take [preventive treatment].”

Fear of getting sick like family
members

Female, group 7

When [my husband] coughed, he coughed up so much blood, almost half a bag of blood.
Looking at him, I prayed to have strength for the sake of my child. So I started to take the
[preventive treatment]. . .I saw [my husband] and said, “I do not want this to happen to me.”

Uptake (barrier)

Insurance status

Nurse, group 8

Here in Peru, we have two types of [public] insurance: the one from the Ministry of Health is
SIS, which is what we work with, and EsSALUD [employer-based]. Many of our patients and
families work and have other insurance, and sometimes these are the people who get
[preventive] treatment prescribed. But because they have EsSALUD insurance, we cannot give
them the isoniazid, and we cannot give it to their children. [EsSALUD hospitals] do not have
isoniazid, so these patients or their family members come back and ask us to please give them
[isoniazid], but it is complicated for us to give medications to a person who has a different
insurance.

Completion
(facilitator)

Family support

Female, group 4

At times I cannot go [to the health facility to pick up medications]. And my mother, because she
is always going there, she picks them up for everyone and brings them to us.

Community health workers offer
support

Female, group 3

[Community health workers] have more training to be able to give you information. And if you
have any doubts, you ask them, and they know how to respond. In contrast, a family member at
times will tell you “fine, well, take [the medication] or don’t take it.”

Personal strategies for remembering
to take medications

Females, group 4

Participant 1: “I leave the pills on the table to remind myself” Participant 2: “I put them in my
wallet.”

SMS reminders help people
remember to take medications

Female, group 2

They are hanging over their phones all day—they eat like that, have breakfast like that, with
their phones. So when [the SMS] comes, with its notification tone, they remember.

Medication fatigue and long
treatment

Female, group 6

It has been very difficult for my daughter. She did not want to take [preventive treatment]. She
took it for the first months. Then she got tired of it, she was sick of it and did not want to take it.
She shouted and cried ‘I don’t want these pills.’

Anticipated or experienced adverse
events

Female, group 1

When my brother-in-law, when he takes [preventive treatment], he tells me that it gives him
nausea, or maybe affects his liver. Well, I would like to take three months and no more.

Inconvenience of weekly
medication refills

Female, group 5

At times, we do not have the time to pick up the mediations weekly. There is no time to go and
pick them up. In my case, I work in rotating shifts, and sometimes I do not have time to go. . ..
Could medication pickups be every two weeks instead? Weekly is very short.

Uptake
(facilitator)

Completion
(barrier)

Difficulty giving pills to children

Female, group 3

My son suffers taking it. Although he chews it, the bitter flavor stays in his mouth, and he cries.

Forgetting while busy

Female, group 5

Sometimes I would go to the health facility early with my daughter, or I would have something
to do early, and I would come back late. And on these days I did not take the pills because I left
the house very early and I left the pills at home.

SMS reminders are not useful for
everyone

Male, group 1

There are times when one may be sent a message–let’s say one sees it in the afternoon. . .but the
person who saw it in the afternoon may continue their routine into the night and forget.

Additional supporting quotations can be found in S4 Table.
https://doi.org/10.1371/journal.pone.0247411.t003
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While completion of the TB preventive cascade was only 18–34% among contacts and poorer
among health care workers and people in congregate settings, these results are consistent with
what programs in high-income countries often achieve; a systematic review of the TB preventive care cascade, in which the majority of studies came from high-income countries, estimated
cascade completion to be 19% globally [23]. Moreover, as a negligible number of adults in
Peru currently access preventive treatment [18], this study represents an important initial step
to expanding access. We found that TB infection testing and treatment were acceptable in this
population, with >90% of participants completing testing and initiating treatment if prescribed. The biggest gaps in the care cascade were in completing evaluation following a positive
test and having doctors prescribe preventive treatment to participants with TB infection [12].
Our intervention successfully expanded TB infection testing, with over 90% of all participant groups completing testing, and over 90% of adults accepting IGRA. From a staffing standpoint, using IGRA instead of TST made the intervention easier to implement because testing
required only a single participant visit, and phlebotomy could be performed by technicians
rather than nurses. However, our intervention benefitted from a donation of IGRA kits and a
laboratory with experience performing IGRA. While studies from high-income countries have
suggested that IGRA testing is more cost-effective than TST [29], either can be used to ensure
that people with TB infection are identified for care.
The limited acceptability of preventive treatment among physicians is a major barrier to
raising the standard of care, and to achieving global goals for TB elimination. Health care
workers in our focus group suggested that clear messaging from the national or local TB program is necessary to address the perceived lack of prioritization of preventive treatment. However, the presence of strong recommendations is not sufficient for ensuring guideline
compliance. TB preventive treatment for people living with HIV has been recommended by
WHO since 2011 [8], and nearly all PEPFAR-supported countries incorporated this recommendation into their national guidelines. Yet, in a 2017 survey, only 60% of these countries
reported nationwide implementation [30]. Ensuring that providers adopt evidence-based recommendations requires not only promoting awareness of national guidelines and international recommendations, but also targeted training, supervision, and infrastructure
strengthening [31]. It will thus require significant effort to re-educate providers after decades
of international health agency recommendations to focus TB preventive treatment only on
child contacts <5 and people living with HIV—a standard of care that not only left many
exposed and at-risk individuals untreated but was significantly different than practices that
were propagated in wealthy countries [32].
In our study, completion of TB preventive treatment (72%) was relatively high compared to
what has been reported in the literature [23,33], and adults were as likely to complete treatment as children. The fact that all participants accepted at least one option from an array of
patient-centered supports suggests the importance of built-in programmatic flexibility. Overall, the adherence barriers that participants identified could be addressed through policy
changes, without major infrastructural change. In health systems that use isoniazid-based preventive treatment, dispensing medications monthly and offering a child-friendly isoniazid formulation could help address the inconvenience of frequent pickups and the difficulty of
administering pills to children. Other barriers such as medication fatigue and adverse events
could be addressed by making newer, shorter regimens available. For example, a 4-month
rifampicin regimen has fewer adverse events [34], and shortened regimens have better treatment completion [35–37].
We found health care workers and staff and residents of congregate settings were much less
likely to complete the TB infection care cascade compared to contacts of patients with TB disease. However, our qualitative research was focused on testing and treatment for contacts, who
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comprised the majority of our target population. More work is required to understand the
local barriers to TB infection testing and treatment for health care workers and people in congregate settings. Among health care workers in the United States, concern over adverse events
and the stigma of TB preventive treatment are barriers to accepting TB treatment [38]. It is
possible that similar concerns among Peruvian health care workers may explain why many
were willing to be tested but few accepted treatment. Alternatively, lack of familiarity with
IGRA among health workers could have also contributed to poor follow-up for positive
results.
Strengths of our study include the structured implementation science approach and the
integration of both quantitative and qualitative methods to evaluate acceptability and feasibility. This approach allowed us to both evaluate the performance of the intervention as a whole
and understand how different elements of the intervention affected the feasibility of changing
practice around TB infection testing and preventive treatment. This knowledge is important
not only for program improvement in Peru, but also for highlighting programmatic considerations that may apply to other settings where TB preventive treatment has to date been
restricted to young children and people living with HIV.
Our study had several important limitations related to the limited data collection that was
feasible in the context of a programmatic intervention whose goal was to maximize reach. We
did not collect comprehensive information from medical records, which would have been
required to rigorously assess eligibility for TB infection treatment under national policy guidelines. Because we did not collect data on all the possible contraindications for TB preventive
treatment, the number of participants we classified as eligible is a maximum estimate, and the
percentage who were prescribed treatment is likely somewhat higher than what we have
reported. Even so, prescription of TB preventive treatment to adult contacts was so low that
the conclusion of suboptimal prescription is likely still valid.
Our study was also limited by the approach of using only focus group discussions held for
intervention planning and feedback for our qualitative research. The number of groups was
pre-determined by resource and time constraints. While certain themes (e.g., the importance
of support from family and community health workers) arose repeatedly among different
groups of contacts, our sample size was insufficient to achieve thematic saturation, and our
sampling strategy prevented us from capturing the full diversity of relevant experiences. For
example, because we recruited participants from families receiving preventive treatment, our
insight into barriers to evaluation and treatment initiation was limited. Moreover, we held
only one focus group discussion with health care workers and none with residents or staff of
congregate settings. Finally, while we attempted to recruit both men and women for focus
groups, most men refused because they had to work during the times that the focus groups
were held; therefore, we were unable to gain much insight into the experiences of men or into
how barriers may differ between men and women. For instance, working men might have
identified barriers related to losing income in order to pick up medications or attend clinic
appointments [39].

Conclusions
In conclusion, expanding access to testing and treatment of TB infection in countries that have
only prioritized children <5 and people living with HIV requires understanding facilitators
and barriers to the care cascade. We observed high uptake of testing and completion of preventive treatment when we offered convenient TB infection testing and individualized community-based treatment support. However, completion of evaluation following a positive
infection test and prescription of preventive treatment were suboptimal, suggesting the need
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for additional efforts to close these gaps. Solutions exist: patient incentives have been shown to
be effective for increasing the completion of evaluation [40], while training, mentorship, and
supervision for providers will be important to support the transition to best-practice care for
TB infection [31]. These lessons can inform the efforts of coalitions seeking to implement a
comprehensive approach to TB elimination that includes treatment of TB infection.
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